MUVON featured by Startupticker

Muvon
Jun 2, 2021
1 min read

MUVON was featured in an article by Startupticker describing our regenerative approach for the treatment of incontinence and the progress our fantastic team has made so far!

Read the article here.

Recent Posts

See All

MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025

UVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the last patient in its phase 2 clinical study.

Personalized approach to muscle regeneration holds promise for longevity - Interview with Longevity.Technology

MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference

MUVON featured by Startupticker

Recent Posts

Comments

LINKS

ABOUT

SOCIAL